Exploring sirolimus as potential alternative therapy for persistent AMDAnti-vascular endothelial growth factor (VEGF) therapy is highly successful, but as Raj Maturi, MD, pointed out, also has some limitations.
Sirolimus shows promise for posterior segment non-infectious uveitisIntravitreal sirolimus 400 mcg (Ospiria, Santen) demonstrated positive results in pivotal trials investigating it as a treatment for non-infectious uveitis of the posterior segment. A New Drug Application is under FDA review. retinal treatment results take center stage in 2015Studies of the efficacy of anti-vascular endothelial growth factor (VEGF), gene therapies, and slow-release drug delivery systems took center stage among treatments for retinal disorders in 2015. In addition to studies already under way, others are about to begin.
Pharmacokinetics data suggests sirolimus activity confined to eyeSerial measurements of sirolimus blood concentrations after intravitreal injection show the maximum concentration achieved was below the level generally associated with systemic immunosuppression.
Drug approved for rare, lung disease that strikes younger womenLymphangioleiomyomatosis (LAM) is a rare, progressive lung disease that primarily affects women of childbearing age. The FDA has approved sirolimus (Rapamune, Pfizer) as the first drug to treat LAM. Rapamune was originally approved to prevent organ rejection.
FDA drug approvals-May 2015FDA actions in brief, complete response, breakthrough therapy designation, fast-track designations, orphan drug designations
FDA drug approvals-February 2015FDA actions in brief, priority review, breakthrough designations, orphan drug designations
Laser-based combo therapy effective for angiofibromaA new study suggests that laser technology combined with a new topical therapy is effective in treating angiofibromas, characteristically seen in patients with tuberous sclerosis.